---
title: "Ocugen, Inc. (OCGN.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/OCGN.US.md"
symbol: "OCGN.US"
name: "Ocugen, Inc."
industry: "Biotechnology"
datetime: "2026-05-20T12:58:37.811Z"
locales:
  - [en](https://longbridge.com/en/quote/OCGN.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/OCGN.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/OCGN.US.md)
---

# Ocugen, Inc. (OCGN.US)

## Company Overview

Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel recombinant fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.ocugen.com](https://www.ocugen.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:16.000Z

**Overall: D (0.79)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 237 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -1.26% |  |
| Net Profit YoY | -24.64% |  |
| P/B Ratio | 73.43 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 426266484.80 |  |
| Revenue | 4465000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -660.00% | E |
| Profit Margin | -1605.22% | E |
| Gross Margin | 26.35% | C |
| Revenue YoY | -1.26% | D |
| Net Profit YoY | -24.64% | D |
| Total Assets YoY | -11.72% | E |
| Net Assets YoY | -63.52% | E |
| Cash Flow Margin | 82.88% | C |
| OCF YoY | -1.26% | D |
| Turnover | 0.07 | E |
| Gearing Ratio | 89.80% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Ocugen, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-1.26%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-24.64%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "73.43",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "426266484.80",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "4465000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-660.00%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-1605.22%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "26.35%",
          "rating": "C"
        },
        {
          "name": "Revenue YoY",
          "value": "-1.26%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "-24.64%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-11.72%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-63.52%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "82.88%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-1.26%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "0.07",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "89.80%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -5.95 | 397/386 | - | - | - |
| PB | 73.43 | 440/386 | 149.40 | 108.73 | 20.37 |
| PS (TTM) | 95.47 | 257/386 | 113.37 | 85.94 | 67.66 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-11T04:00:00.000Z

Total Analysts: **7**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 6 | 86% |
| Overweight | 1 | 14% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 1.30 |
| Highest Target | 22.00 |
| Lowest Target | 7.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/OCGN.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/OCGN.US/norm.md)
- [Related News](https://longbridge.com/en/quote/OCGN.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/OCGN.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**